NCT01670110View on ClinicalTrials.gov

Pasireotide LAR in Severe Polycystic Liver Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Somatostatin AnalogsPolycystic Liver DiseaseAutosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Liver Disease
Interventions
DRUG

Pasireotide LAR

Injectible, 60mg per month

DRUG

Placebo

To be injected once per month

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT01670110 - Pasireotide LAR in Severe Polycystic Liver Disease | Biotech Hunter | Biotech Hunter